MedX Announces Proposed Non-Brokered Private Placement to Raise up to $2,500,000 and Stock Option Grants
MWN-AI** Summary
MedX Health Corp. (TSX-V: MDX) has announced its intent to raise up to $2,500,000 through a proposed Non-Brokered Private Placement. The offering will consist of up to 33,333,334 Units, each priced at $0.075. Each Unit consists of one common share and one-half of a Share Purchase Warrant, which can be exercised to purchase a full common share at $0.10 within a year of issue. The fundraising initiative is contingent on achieving a minimum subscription of $500,000 and obtaining necessary regulatory approvals.
The proceeds from this private placement are earmarked for the ongoing development of MedX’s innovative SIAscopy® technology, which is integrated into the DermSecure® telemedicine platform. This initiative aims to advance the company's efforts to launch its technology within the occupational health sector, along with supporting general corporate needs. Notably, certain insiders may also participate in this placement.
Additionally, MedX has granted 500,000 stock options to a consultant under its Incentive Stock Option Plan, exercisable at $0.10 per share for a duration of five years. Currently, a total of 30,000,000 options are allocated under this plan, of which 23,050,000 are already granted, while 6,950,000 remain available for future grants.
MedX Health, based in Ontario, Canada, specializes in non-invasive skin assessments and teledermatology. Its proprietary technologies, particularly SIAscopy®, have gained clearance from multiple health authorities, including Health Canada and the U.S. FDA, making it a leader in the rapidly evolving field of telemedicine.
For more information, visit MedX's official website at https://www.medxhealth.com.
MWN-AI** Analysis
MedX Health Corp. (TSX-V: MDX) has recently announced a proposed non-brokered private placement aimed at raising up to $2.5 million through the issuance of up to 33,333,334 units priced at $0.075 each. This plan includes half-share purchase warrants, exercisable at $0.10 within one year, potentially providing a path for investors to benefit from future appreciation in the company’s share price.
This capital raise is strategically earmarked for enhancing the SIAscopy® technology within the DermSecure® telemedicine platform and expanding its applicability in the occupational health sector. Given the rising demand for teledermatology solutions, particularly amidst ongoing shifts toward virtual healthcare, investing in MedX at this stage could be viewed favorably. The company's strong regulatory standing in multiple jurisdictions (including Health Canada and the FDA) further supports its position as a leader in non-invasive skin assessments.
Investors should note that a minimum of $500,000 is required in subscriptions for the placement to proceed, reflecting a prudent approach to ensure sufficient interest in the offering. The anticipated participation of insiders could signal their confidence in the company's future, which is a positive indicator for prospective investors.
Moreover, the grant of 500,000 stock options at $0.10 per share aligns stakeholders' interests with that of the company's growth trajectory, effectively investing in the long-term performance of MedX. The total options available for grant shows effective management of employee incentives, albeit with some issuance already consumed.
In light of these developments, the current share price of $0.075 represents an attractive entry point, given the company's growth initiatives and the potential for upward movement if market conditions align. However, investors should conduct thorough due diligence and monitor regulatory approvals which could impact the finalization of this private placement.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX ) is pleased to announce that it is proposing to raise up to $2,500,000 by way of a Non-Brokered Private Placement of up to 33,333,334 Units at $0.075 per Unit (“Unit”). Each Unit will be comprised of One (1) fully paid common share and One-half (1/2) of a Share Purchase Warrant; each whole Share Purchase Warrants (“ Warrant ( s )”) will be exercisable to purchase One (1) further Common Share at the price of $0.10, during the period of one year commencing on the date of issue. Closing of the Placement, which may take place in tranches, will be subject to receipt of subscriptions for a minimum of $500,000 and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Funds raised on this placement will be directed towards continuing development of the Company’s leading edge SIAscopy ® on DermSecure ® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. It is anticipated that certain Insiders may participate in this Placement. Closing of the Placement will be subject to all relevant TSXV or other approvals and compliance with all applicable policies. Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent’s warrants (“ Agent’s Warrant(s) ”) equal to 8% of subscriptions introduced by such agent(s). Each Agent’s Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.09, a unit, comprised of One (1) fully paid Common Share and one-half (1/2) of a non-transferable agent’s share purchase warrant; each whole agent’s share purchase warrant (“ Agent’s Share Purchase Warrant ”), will entitle the holder to acquire one additional Common Share at the price of CAD$0.10. The Agent’s Warrants and any Agent’s Share Purchase Warrants that may be issued pursuant to exercise of an Agent’s Warrant, if not exercised, will expire one year following the date of issuance of the original Agent’s Warrant.
The Company also announces that a total of 500,000 stock options have been granted pursuant to the Company’s Incentive Stock Option Plan to a consultant. The options are exercisable at the price of $0.10 per share, valid for a period of five years and vest immediately. At this time there is a total of 30,000,000 options available for grant under the Company’s Incentive Stock Option Plan, of which a total of 23,050,000 (including the most recent grant) are currently subject to grants, at a weighted average exercise price of $0.1024, and 6,950,000 remain available for grant under the Plan.
About MedX Health Corp.:
MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ® , and its secure, cloud-based patient management system, DermSecure ® . SIAscopy ® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin’s surface. Visit: https://www.medxhealth.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250725531217/en/
MedX Health Corp.
Mike Druhan, President Dermatological Services
mike.druhan@medxhealth.com
(+1) 905-599-7852
FAQ**
What specific milestones does MedX Health Corp. MDX:CC aim to achieve with the $2,500,000 raised through the Non-Brokered Private Placement, particularly regarding the development of its SIAscopy® technology?
How does MedX Health Corp. MDX:CC plan to utilize the funds from the private placement to penetrate the occupational health marketplace, and what strategies will be employed?
Could you elaborate on the potential participation of insiders in the non-brokered private placement and how it affects shareholder confidence in MedX Health Corp. MDX:CC?
What are the expected regulatory challenges or timelines that MedX Health Corp. MDX:CC anticipates in securing approvals for this financing and advancing its product offerings?
**MWN-AI FAQ is based on asking OpenAI questions about Medx Health Corp. (TSXVC: MDX:CC).
NASDAQ: MDX:CC
MDX:CC Trading
0.0% G/L:
$0.065 Last:
6,000 Volume:
$0.06 Open:
